Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit

MORRISVILLE, N.C., Dec. 11, 2018 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or
“Novan”) (NASDAQ:NOVN) today announced that clinical results from the Company’s Phase
1b trial with SB414 cream for the treatment of atopic dermatitis will be presented at the
3rd Inflammatory Skin Disease Summit in Vienna, Austria.